This report was first published by Endpoints News. To see the original version, click here
Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the US.
The open-label Phase 2/3 uveal melanoma trial tested the biotech’s protein kinase C inhibitor called darovasertib in combination with Pfizer’s Xalkori. The primary endpoint looked at median progression-free survival, with Ideaya setting a 5.5-month success benchmark.
您已阅读18%（524字），剩余82%（2376字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。